keyword
MENU ▼
Read by QxMD icon Read
search

Intravesical therapy

keyword
https://www.readbyqxmd.com/read/28920525/can-urologists-accurately-stage-and-grade-urothelial-bladder-cancer-by-assessing-endoscopic-photographs
#1
Snir Dekalo, Haim Matzkin, Nicola J Mabjeesh
Introduction Assessment of urothelial bladder cancer during cystoscopy or transurethral resection of bladder tumour has a significant impact on the urologist's decision-making: treatment with simple outpatient fulguration, required depth of resection, and need of immediate post-surgical intravesical therapy. These choices depend heavily on the urologist's ability to accurately assess pre-biopsy tumour stage and grade. The aim of the study was to determine whether evaluation of photographs taken during transurethral resection of bladder tumour can reliably characterize a tumour's stage and grade...
January 1, 2017: Journal of Telemedicine and Telecare
https://www.readbyqxmd.com/read/28898400/intravesical-electromotive-drug-administration-for-non-muscle-invasive-bladder-cancer
#2
REVIEW
Jae Hung Jung, Ahmet Gudeloglu, Halil Kiziloz, Gretchen M Kuntz, Alea Miller, Badrinath R Konety, Philipp Dahm
BACKGROUND: Electromotive drug administration (EMDA) is the use of electrical current to improve the delivery of intravesical agents to reduce the risk of recurrence in people with non-muscle invasive bladder cancer (NMIBC). It is unclear how effective this is in comparison to other forms of intravesical therapy. OBJECTIVES: To assess the effects of intravesical EMDA for the treatment of NMIBC. SEARCH METHODS: We performed a comprehensive search using multiple databases (CENTRAL, MEDLINE, EMBASE), two clinical trial registries and a grey literature repository...
September 12, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28892597/adult-male-stress-and-urge-urinary-incontinence-a-review-of-pathophysiology-and-treatment-strategies-for-voiding-dysfunction-in-men
#3
Eric Chung, Darren J Katz, Christopher Love
BACKGROUND: Male urinary incontinence adversely affects health-related quality of life and is associated with significant psychosexual and financial burden. The two most common forms of male incontinence are stress urinary incontinence (SUI) and overactive bladder (OAB) with concomitant urge urinary incontinence (UUI). OBJECTIVE: The objectives of this article are to briefly review the current understandings of the pathophysiological mechanisms in SUI and OAB/UUI, and offer a set of practical, action-based recommendations and treatment strategies...
September 2017: Australian Family Physician
https://www.readbyqxmd.com/read/28891795/-intravesical-botulinum-toxin-under-local-anestesia-as-ambulatory-procedure
#4
José Javier Fabuel Alcañiz, Laura Martínez Arcos, Miguel Jimenez Cidre, Francisco Javier Burgos Revilla
Bladder hyperactivity is described as the presence of "voiding urgency, generally associated with increased daytime frequency and nocturia, with or without urinary incontinence, in the absence of urinary tract infection or other obvious pathology". Onabotulinum toxin A (BTA) is a recommendable therapeutic option in case of failure, contraindication or refusal of the conservative therapy or other non-pharmacological therapies. The injection of BTA in the detrusor has been performed under local, regional or general anesthesia either in the conventional or major ambulatory surgery operative room or in the cystoscopy room...
September 2017: Archivos Españoles de Urología
https://www.readbyqxmd.com/read/28889718/-reactive-arthritis-during-the-second-course-of-intravesical-bcg-therapy-requiring-administration-of-methotrexate-a-case-report
#5
Ryosuke Ikeuchi, Takuro Sunada, Takeshi Yoshikawa, Toru Yoshida, Yuya Tabuchi, Yoichiro Kajita, Takehiko Segawa
Reactive arthritis, formerly called Reiter's syndrome, is one of the rare complications following intravesical instillation of Bacillus Calmette Guerin (BCG). A 58-year-old man was admitted to our hospital because of fever, hyperemia of conjunctiva, and arthralgia following the second course of intravesical instillation of BCG in the treatment of pT1 and pTis bladder cancer. We diagnosed him with reactive arthritis due to the clinical course. Reactive arthritis is usually well controlled with the discontinuation of instillation and administration of nonsteroidal anti-inflammatory drugs (NSAIDs)...
August 2017: Hinyokika Kiyo. Acta Urologica Japonica
https://www.readbyqxmd.com/read/28889387/orthotopic-mouse-models-of-urothelial-cancer
#6
Wolfgang Jäger, Igor Moskalev, Peter Raven, Akihiro Goriki, Samir Bidnur, Peter C Black
Orthotopic mouse models of urothelial cancer are essential for testing novel therapies and molecular manipulations of cell lines in vivo. These models are either established by orthotopic inoculation of human (xenograft models) or murine tumor cells (syngeneic models) in immunocompromised or immune competent mice. Current techniques rely on inoculation by intravesical instillation or direct injection into the bladder wall. Alternative models include the induction of murine bladder tumors by chemical carcinogens (BBN) or genetic engineering (GEM)...
2018: Methods in Molecular Biology
https://www.readbyqxmd.com/read/28888400/characterization-of-inflammasome-related-genes-in-urine-sediments-of-patients-receiving-intravesical-bcg-therapy
#7
Giulia Poli, Giovanni Cochetti, Andrea Boni, Maria Giulia Egidi, Stefano Brancorsini, Ettore Mearini
BACKGROUND: Nowadays, the intravesical Bacillus Calmette-Guérin (BCG) instillation is the method of choice for the postsurgical treatment of high-grade nonmuscle-invasive bladder cancer , to reduce both recurrence rate and risk of progression. BCG is hypothesized to correct the immune system disequilibrium occurring during carcinogenesis, through an immunostimulation with detrimental effects for tumoral cells. Inflammation plays a crucial role in tumor progression. The deregulation of inflammasomes upon carcinogenesis underlines its importance both in physiologic and pathologic human conditions...
September 6, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28884476/probiotics-for-preventing-urinary-tract-infection-in-people-with-neuropathic-bladder
#8
REVIEW
Swee-Ling Toh, Claire L Boswell-Ruys, Bon San B Lee, Judy M Simpson, Kate R Clezy
BACKGROUND: Neuropathic or neurogenic bladder describes a process of dysfunctional voiding as the result of injury in the brain, spinal cord or nerves innervating the bladder. People with neuropathic bladder, such as from spinal cord injury (SCI), are at significant risk of morbidity from urinary tract infections (UTI). Effective methods to prevent UTI in people with SCI have been sought for many years. Probiotics (micro-organisms that exert beneficial health effects in the host) have been recommended for bacterial interference of the urological tract to reduce colonisation by uropathogen and to manage the dual problems of infection and antibiotic resistance...
September 8, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28870862/incidence-clinicopathologic-risk-factors-management-and-outcomes-of-non-muscle-invasive-recurrences-after-complete-response-to-tri-modality-therapy-for-muscle-invasive-bladder-cancer
#9
Alejandro Sanchez, Matthew F Wszolek, Andrzej Niemierko, Rebecca H Clayman, Michael Drumm, Dayron Rodríguez, Adam S Feldman, Douglas M Dahl, Niall M Heney, William U Shipley, Anthony L Zietman, Jason A Efstathiou
PURPOSE: To describe the incidence, clinicopathologic risk factors, management, and outcomes of non-muscle invasive bladder cancer (NMIBC) recurrences after complete response (CR) to tri-modality therapy (TMT) for muscle-invasive bladder cancer (MIBC). MATERIALS AND METHODS: Patients with cT2-4aN0M0 MIBC (n=342) and CR after TMT were reviewed retrospectively (1986-2013). Using competing risks analyses, the association between baseline clinicopathologic variables and NMIBC outcomes was examined...
September 1, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28866819/fluorescence-in-situ-hybridization-as-prognostic-predictor-of-tumor-recurrence-during-treatment-with-bacillus-calmette-gu%C3%A3-rin-therapy-for-intermediate-and-high-risk-non-muscle-invasive-bladder-cancer
#10
Esmee I M L Liem, Joyce Baard, Evelyne C C Cauberg, Mieke T J Bus, D Martijn de Bruin, M Pilar Laguna Pes, Jean J M C H de la Rosette, Theo M de Reijke
A significant number of patients with intermediate- or high-risk bladder cancer treated with intravesical Bacillus Calmette-Guérin (BCG) immunotherapy are non-responders to this treatment. Since we cannot predict in which patients BCG therapy will fail, markers for responders are needed. UroVysion(®) is a multitarget fluorescence in situ hybridization (FISH) test for bladder cancer detection. The aim of this study was to evaluate whether FISH can be used to early identify recurrence during treatment with BCG...
September 2, 2017: Medical Oncology
https://www.readbyqxmd.com/read/28862730/intravesical-glycosaminoglycan-therapy-overall-conclusions
#11
Stéphane Droupy, Jonathan C Goddard
No abstract text is available yet for this article.
August 17, 2017: Urologia
https://www.readbyqxmd.com/read/28834453/intravesical-rad-ifn%C3%AE-syn3-for-patients-with-high-grade-bacillus-calmette-guerin-refractory-or-relapsed-non-muscle-invasive-bladder-cancer-a-phase-ii-randomized-study
#12
Neal D Shore, Stephen A Boorjian, Daniel J Canter, Kenneth Ogan, Lawrence I Karsh, Tracy M Downs, Leonard G Gomella, Ashish M Kamat, Yair Lotan, Robert S Svatek, Trinity J Bivalacqua, Robert L Grubb, Tracey L Krupski, Seth P Lerner, Michael E Woods, Brant A Inman, Matthew I Milowsky, Alan Boyd, F Peter Treasure, Gillian Gregory, David G Sawutz, Seppo Yla-Herttuala, Nigel R Parker, Colin P N Dinney
Purpose Many patients with high-risk non-muscle-invasive bladder cancer (NMIBC) are either refractory to bacillus Calmette-Guerin (BCG) treatment or may experience disease relapse. We assessed the efficacy and safety of recombinant adenovirus interferon alfa with Syn3 (rAd-IFNα/Syn3), a replication-deficient recombinant adenovirus gene transfer vector, for patients with high-grade (HG) BCG-refractory or relapsed NMIBC. Methods In this open-label, multicenter (n = 13), parallel-arm, phase II study ( ClinicalTrials...
August 23, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28827195/impact-of-regular-cannabis-use-on-biomarkers-of-lower-urinary-tract-function
#13
Balachandar Nedumaran, Pratyaydipta Rudra, Jeanette Gaydos, Sushil Kumar, Randall B Meacham, Ellen L Burnham, Anna P Malykhina
OBJECTIVES: To evaluate the differences in the composition and quantities of the urine peptides in regular cannabis users and non-users by LC-MS/MS analysis. MATERIALS AND METHODS: Urine specimens from healthy control subjects and cannabis users were utilized to identify the differences in number and quantity of urine proteins LC-MS/MS analysis. Significantly altered proteins were determined by a permutation testing statistical method. Heat map, dendrogram, pathways and network analyses were performed to assess the degree of expression and potential relationships between proteins in both groups...
August 18, 2017: Urology
https://www.readbyqxmd.com/read/28821265/poncet-s-disease-after-the-intravesical-instillation-of-bacillus-calmette-gu%C3%A3-rin-bcg-a-case-report
#14
Paula Cíntia Machado Sampaio, Yan Garcia Lira, Hellen Yuki Umemura Ribeiro, Fernanda de Paula Moreira, Maitê Silva Martins Gadelha, Sérgio Ferreira Santos da Cruz
BACKGROUND: Poncet's disease is a rare syndrome characterized by articular impairment in a form of rare tuberculid. One of the theories of its cause involves an autoimmune response induced by the intravesical administration of the Calmette-Guerin Bacillus or the treatment of bladder carcinoma. Furthermore, there may be an appearance of oligoarticular or polyarticular arthritis, beginning 1-3 months after the start of therapy. Few physicians know the disease and the literature related to that syndrome is scarce and restricted to case reports, which contributes to its under diagnosis...
August 18, 2017: BMC Research Notes
https://www.readbyqxmd.com/read/28818454/the-anti-tumor-effect-of-intravesical-administration-of-normal-urothelial-cells-on-bladder-cancer
#15
Chi-Ping Huang, Chi-Cheng Chen, Chih-Rong Shyr
BACKGROUND AIMS: Urothelial bladder cancer (UBC) is the second most common cancer of the genitourinary tract and for advanced forms of the disease it has a high mortality rate. There are no approved new molecularly targeted agents or chemotherapeutics for advanced UBC beyond cisplatin-based chemotherapy except the recently approved anti-programmed death ligand 1 (anti-PD-1/PD-L1) antibody. With complex genetic and epigenetic alterations in tumors, despite several druggable targets identified, to cure UBC is still a challenging unmet medical need...
August 14, 2017: Cytotherapy
https://www.readbyqxmd.com/read/28815048/society-for-immunotherapy-of-cancer-consensus-statement-on-immunotherapy-for-the-treatment-of-bladder-carcinoma
#16
Ashish M Kamat, Joaquim Bellmunt, Matthew D Galsky, Badrinath R Konety, Donald L Lamm, David Langham, Cheryl T Lee, Matthew I Milowsky, Michael A O'Donnell, Peter H O'Donnell, Daniel P Petrylak, Padmanee Sharma, Eila C Skinner, Guru Sonpavde, John A Taylor, Prasanth Abraham, Jonathan E Rosenberg
The standard of care for most patients with non-muscle-invasive bladder cancer (NMIBC) is immunotherapy with intravesical Bacillus Calmette-Guérin (BCG), which activates the immune system to recognize and destroy malignant cells and has demonstrated durable clinical benefit. Urologic best-practice guidelines and consensus reports have been developed and strengthened based on data on the timing, dose, and duration of therapy from randomized clinical trials, as well as by critical evaluation of criteria for progression...
2017: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/28808734/what-is-the-true-catheterization-rate-after-intravesical-onabotulinumtoxina-injection
#17
Devin N Patel, Juzar Jamnagerwalla, Justin Houman, Jennifer T Anger, Karyn S Eilber
INTRODUCTION AND HYPOTHESIS: A known side effect of intravesical onabotulinumtoxinA (Botox®) injection for overactive bladder (OAB) is urinary retention requiring clean intermittent catheterization (CIC), the fear of which deters patients from choosing this therapy. In clinical practice, patients with an elevated postvoid residual (PVR) are often managed by observation only, providing they do not have subjective complaints or contraindications. We sought to determine the true rate of urinary retention requiring CIC in clinical practice...
August 14, 2017: International Urogynecology Journal
https://www.readbyqxmd.com/read/28808039/preclincial-evaluation-of-intravesical-cisplatin-nanoparticles-for-non-muscle-invasive-bladder-cancer
#18
Max Kates, Abhijit Date, Takahiro Yoshida, Umara Afzal, Pranjali Kanvinde, Taarika Babu, Nikolai A Sopko, Hotaka Matsui, Noah M Hahn, David J McConkey, Alex S Baras, Justin Hanes, Laura Ensign, Trinity J Bivalacqua
PURPOSE: Prior clinical trials evaluating cisplatin for non-muscle invasive bladder cancer (NMIBC) were stopped due to local and systemic toxicity. Currently, there is still a need for improved intravesical therapies, and nanoparticle-based CDDP may be efficacious without the toxicity of free cisplatin observed in the past. EXPERIMENTAL DESIGN: Cisplatin nanoparticles (CDDP NP) were developed using biocompatible poly(L-aspartic acid sodium salt) (PAA), both with and without low and high grafting density of methoxy-polyethylene glycol (PEG)...
August 14, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28807024/society-for-immunotherapy-of-cancer-consensus-statement-on-immunotherapy-for-the-treatment-of-bladder-carcinoma
#19
Ashish M Kamat, Joaquim Bellmunt, Matthew D Galsky, Badrinath R Konety, Donald L Lamm, David Langham, Cheryl T Lee, Matthew I Milowsky, Michael A O'Donnell, Peter H O'Donnell, Daniel P Petrylak, Padmanee Sharma, Eila C Skinner, Guru Sonpavde, John A Taylor, Prasanth Abraham, Jonathan E Rosenberg
The standard of care for most patients with non-muscle-invasive bladder cancer (NMIBC) is immunotherapy with intravesical Bacillus Calmette-Guérin (BCG), which activates the immune system to recognize and destroy malignant cells and has demonstrated durable clinical benefit. Urologic best-practice guidelines and consensus reports have been developed and strengthened based on data on the timing, dose, and duration of therapy from randomized clinical trials, as well as by critical evaluation of criteria for progression...
August 15, 2017: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/28801026/quadruple-immunotherapy-of-bacillus-calmette-gu%C3%A3-rin-interferon-interleukin-2-and-granulocyte-macrophage-colony-stimulating-factor-as-salvage-therapy-for-non-muscle-invasive-bladder-cancer
#20
Ryan L Steinberg, Kenneth G Nepple, Kyla N Velaer, Lewis J Thomas, Michael A O'Donnell
BACKGROUND: Bacillus Calmette-Guérin (BCG) is the most effective initial intravesical therapy for high-grade non-muscle invasive bladder cancer, but many patients still fail. Combination intravesical BCG and interferon (IFN) will salvage some patients but results remain suboptimal. OBJECTIVE: We hypothesized that further immunostimulation with intravesical interleukin-2 and subcutaneous granulocyte-macrophage colony-stimulating factor may improve response to intravesical BCG and IFN in patient with prior BCG failure(s)...
August 8, 2017: Urologic Oncology
keyword
keyword
21306
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"